Please assess the completion status of the following clinical trial:

Trial Title: Intravitreal Aflibercept in Wet Age Related Macular Degeneration Patients With an Incomplete Response to Routine Ranibizumab Injections

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~Note: Subjects must meet all of the following inclusion criteria to be eligible for enrollment into the study~1. Age \>50 years~2. Active primary subfoveal choroidal neovascularization (CNV) lesions secondary to AMD including juxtafoveal lesions that affect the fovea as evidenced by Fluorescein Angiography in the study eye~3. Presence of intra or sub retinal fluid on SDOCT in the study eye~4. Current treatment with uninterrupted routine (q35 +/- 7 days) ranibizumab started at least 3 months before Baseline (Week 0), having received at least 3 consecutive ranibizumab injections and no more than 24 injections maximum, with all ranibizumab injection intervals being 35 +/- 7 days apart~5. ETDRS BCVA 20/30 and 20/320 (letter score of 78 to 25) in the study eye~Exclusion Criteria:~Subjects presenting with any of the following will not be included in the study:~1. Presence of purely serous pigment epithelial detachment in the study eye~2. Any scarring or fibrosis involving the center of the fovea in the study eye~3. Prior ocular or systemic treatment/surgery for wet AMD other than ranibizumab IVI monthly (in study the eye)~4. Prior prn or treat and extend treatment with ranibizumab IVI between 3 to 24 months before Baseline (Week 0) in the study eye~5. Prior treatment with systemic anti-VEGF therapy within the last 6 months in the study eye~6. History of vitreous hemorrhage within the last 6 months in the study eye~7. Prior vitrectomy in the study eye~8. History of retinal detachment in the study eye~9. History of macular hole of stage 2 and above in the study eye~10. Presence of retinal pigment epithelial tears or rips involving the macula in the study eye.~11. Any intraocular or periocular surgery/invasive procedure during the previous 6 months except lid surgery in the study eye~12. Prior trabeculectomy or other filtration surgery in the study eye~13. Uncontrolled glaucoma (≥ 25mmHg despite treatment with anti-glaucoma medications) in the study eye~14. Aphakia or pseudophakia with absence of posterior capsule (unless it occurred as a result of a yttrium aluminum garnet (YAG) posterior capsulotomy) in the study eye.~15. Scheduled for intraocular surgery during the study period in the study eye~16. Concurrent retinal disease (i.e. diabetic retinopathy, retinal vein occlusion, retinal detachment, uveitis) in the study eye~17. History of ocular or periocular infection/inflammation in the study eye within the last 4 weeks of screening~18. Pregnant or breastfeeding

- Gender: ALL
- Minimum Age: 51 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Aflibercept (Type: EXPERIMENTAL): Aflibercept 2 mg (0.05 mL or 50 microliters) will be administered by intravitreal injection every 4 weeks for the first 8 weeks, followed by 2 mg (0.05 mL) via intravitreal injection once every 8 weeks for 36 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).